Custom Library Construction & Screening Service for Pet Antibody Discovery
Creative Biolabs' phage display library construction and screening service helps you discover novel therapeutic antibodies for companion animals by leveraging our advanced phage display technology and deep expertise in veterinary immunology. We accelerate your journey from target to therapeutic lead by constructing diverse, species-specific phage display libraries and implementing rigorous, multi-parameter screening cascades to identify high-affinity and functionally active antibody candidates, paving the way for innovative treatments for pets.
Introduction
Creative Biolabs provides an end-to-end solution for discovering therapeutic antibody candidates tailored for veterinary applications. We empower your research by cusomizaion of antibody libraries and identifying promising leads with desired specificity and affinity for your target of interest in companion animal species. We focus on translating your scientific insights into tangible therapeutic candidates. Our deliverables include fully characterized antibody fragments (like scFvs or Fabs) or full-length antibodies, comprehensive data packages detailing binding kinetics and specificity, and the genetic sequences of your lead candidates. We solve the critical problem of finding highly specific and potent antibodies against challenging targets in non-human species, thus accelerating the development of novel biotherapeutics for unmet needs in animal health.
Workflow
Our streamlined workflow ensures rapid and efficient identification of target-specific binders from our premade canine and feline naïve, immune, or synthetic antibody libraries.
To initiate the project, we typically require one or more of the following:
- Purified Target Antigen: Sufficient quantity and purity of the protein, peptide, or other molecule against which antibodies are desired. Details on post-translational modifications or specific conformations may be crucial.
- Target-Expressing Cell Lines: For targets that are membrane-bound or require a native cellular context for proper folding and presentation.
- Sequence Information or DNA/RNA: For targets where recombinant expression is part of the antigen production strategy, or for constructing immune libraries from specific animal donors.
| Workflow | Description | Outcome | Timeframe |
|---|---|---|---|
| Antigen Preparation and QC | If Creative Biolabs is producing the antigen, this involves gene synthesis, expression, purification, and rigorous quality control (e.g., SDS-PAGE, Western Blot, endotoxin testing). If client-provided, we perform incoming QC. | High-quality, well-characterized antigen suitable for library panning. | 2-4 week |
| Phage Display Library Construction |
|
A highly diverse phage display library (typically >108-1010 individual clones) displaying a wide repertoire of antibody fragments. Library quality is assessed by titration and diversity analysis. | Project dependent |
| Biopanning | Iterative rounds of incubating the phage library with the immobilized target antigen. Non-specifically bound phages are washed away, and specifically bound phages are eluted, amplified in E. coli, and used for the next round of panning under increasing stringency. | Enrichment of phage clones displaying antibodies with high affinity and specificity for the target antigen. | 2-4 weeks |
| Hit Identification and Primary Screening | Individual phage clones from the enriched pool are isolated. Their binding to the target antigen (and counter-targets for specificity screening) is assessed using methods like phage ELISA. | Identification of a panel of unique antigen-specific phage antibody clones (hits). | 1-2 weeks |
| Antibody Characterization | Promising antibody fragments (e.g., scFv, Fab) from selected hits are subcloned into expression vectors, expressed (typically in E. coli or mammalian cells), purified, and characterized for binding affinity (e.g., ELISA, SPR, BLI), specificity, and preliminary developability assessment. | Purified antibody fragments with confirmed binding properties and sequences. | 2-4 weeks |
| Final Deliverables |
|
||
Fig 1. Schematic overview of phage biopanning.1,2
Why Choose Us?
Related Services
Premade Phage Display Library Screening
Access our existing high-diversity naïve or species-specific (e.g., canine, feline) libraries for rapid screening against your target. Ideal for proof-of-concept studies or when custom library construction is not immediately required.
Antibody Characterization
Comprehensive biophysical and functional characterization of your lead antibody candidates, including affinity measurement (SPR/BLI), epitope binning, specificity analysis, stability studies, and in vitro functional assays.
Antibody Engineering
Optimize your lead antibodies for therapeutic use through services like affinity maturation, caninization/felinization, Fc engineering (for tailored effector functions or half-life extension), and antibody fragment formatting (e.g., scFv to Fab or full IgG).
FAQs
Partner with Creative Biolabs
Creative Biolabs is your dedicated partner for advancing pet health through innovative therapeutic antibody discovery. Our specialized phage display library construction and screening services, combined with a comprehensive suite of antibody engineering and characterization capabilities, provide a robust platform to identify and develop next-generation biologics for companion animals. We are committed to scientific excellence, tailored solutions, and collaborative partnerships to help you achieve your research and development goals.
Ready to start your pet therapeutic antibody discovery project or learn more about how Creative Biolabs can support your research? Please contact our expert team to discuss your phage display library construction and screening project.
References
- Panagides, Nadya et al. "Evaluation of Phage Display Biopanning Strategies for the Selection of Anti-Cell Surface Receptor Antibodies." International journal of molecular sciences vol. 23,15 8470. 30 Jul. 2022, https://doi.org/10.3390/ijms23158470
- Distributed under Open Access license CC BY 4.0, without modification.